Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in bridge-to-transplant patients supported with centrifugal-flow left ventricular assist devices.

Sanjay Chavali,Sumita Barua,Audrey Adji,Desiree Robson,Lisa M Raven,Jerry R Greenfield,Hunter Eckford,Peter S Macdonald,Christopher S Hayward,Kavitha Muthiah

International journal of cardiology（2023）

引用 0|浏览11

暂无评分

摘要

We found SGLT2i to be safe and well-tolerated in the BTT LVAD cohort with no significant difference in rates of infection or haemocompatibility-related adverse events with SGLT2i use. Larger studies will inform further beneficial effects of SGLT2i prescription in this cohort.

查看译文

关键词

SGLT2i = sodium-glucose cotransporter-2 inhibitors,LVAD = left-ventricular-assistdevice,BTT = bridge to transplant,eGFR = estimated glomerular filtration rate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要